PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26492704-6	2015	RESULTS: Ovarian diameter and VEGF expression were significantly lower in the montelukast and cabergoline groups than in the severe OHSS group.	montelukast	78-89	vascular endothelial growth factor A	Rattus norvegicus	30-34	
26492704-9	2015	Montelukast limits VEGF expression, and cabergoline reduces both VEGF and VEGFR-2 expressions; they are both effective therapies for the prevention of severe OHSS.	montelukast	0-11	vascular endothelial growth factor A	Rattus norvegicus	19-23	
19575935-14	2009	MK may be effective in reducing allergic airway inflammation and airway remodeling through VEGF and VEGFR.	montelukast	0-2	vascular endothelial growth factor A	Rattus norvegicus	91-95	
25599748-10	2015	Body weight, ovarian weight, VP, peritoneal fluid VEGF values and VEGF expression were significantly lower in both cabergoline- and montelukast-treated rats than in those not treated OHSS group.	montelukast	132-143	vascular endothelial growth factor A	Rattus norvegicus	50-54	
25599748-10	2015	Body weight, ovarian weight, VP, peritoneal fluid VEGF values and VEGF expression were significantly lower in both cabergoline- and montelukast-treated rats than in those not treated OHSS group.	montelukast	132-143	vascular endothelial growth factor A	Rattus norvegicus	66-70